Thursday, March 21, 2013

Biosimilars....


After my M Tech from BITS Pilani, i got placed with biotech pharma R&D where in i was asked to choose my task from being a molecular biologist to fermentation and further downstream processing. I chose to be a molecular biologist, then went ahead for Pharma consulting and the journey still continues. I have been working in the Biosimilar arena for around 8 years with experience in working in R&D to CI in terms of PMR services in terms of development of specific recombinant proteins and Mabs

In the late 2000's some big pharma companies showed a big picture to the world related to their huge investment in this arena and there were some who slowly started developing their pipeline. With the block buster era loosing its glory...biosimilars will mark the difference and emerging markets will be the bait for the big pharma's....in present Europe has been the front runner for biosimilar promotion but we can't negate the emerging markets (China, India and South Korea).....they are the new junctures for growth and promotions of biosimilars and will emerge as destination for biosimilar developments.......


Wednesday, January 30, 2013

After Daniel Vasella.......will Novartis maintain its Charm???


I have read a lot about Daniel Vasella, how he changed the fortune of Novartis,.......In Basel two companies campuses are looked for, one is Roche and another is Novartis.......Both with different work style and generally people tell me that none of the companies recruit other's employees......I am unable to confirm it.....but working in Novartis Basel office is a different ball game.......

Daniel Vasella was the man who made a difference for the company and some analyst reports have predicted that Novartis will be heading for number 1 position in terms of Pharma revenues by year 2018......the recent news of Daniel Vasella quitting as CEO was shocking for me......according to report investors were happy with the decision but we have to see how the market is going to behave further....what will be companies new M&A and R&D policies......time will say if Novartis will maintain its charm? 

Monday, January 07, 2013

Parexel!

Parexel just went into buying out and expending its portfolio in Regulatory approval processes. Though Quintile always had the first mover advantage and icon the smallest baby in the industry has matured quite fast. What i have observed is that PPD and Parexel have slight conservative approach compared to Quintiles and Icon in terms of their portfolio expansion and establishment in new territories. Like Quintiles new move in Biosimilars and RA therapy as such. Parexel went on to penetrate in the field of Biosimilars but more to watch from this CRO in terms of its strategic expansion in APAC, Middle east and Latin America

Friday, January 04, 2013

Whistleblower!

After the provisions in the whistle blower act, pharma has seen many illegal marketing tactics coming out in public, Pfizer has been targeted many a times and it’s still with its competitor Novartis considered the best in the field of Pharma Marketing

We now need to watch how Pfizer is promoting Tofacitinib and Eliquis?

Last month what astonished me that Amgen was ready to pay back around 750 M USD to federal government as it already knew that it had to pay the price for use of illegal marketing tactics for Arnasep. This is not the first case, for the past 20 years we have seen a tremendous increase in these types of marketing tactics by Pharma and biopharma companies to allure physicians and primary health bodies. As Amgen had already kept aside 750 M USD from its revenue. Going forward we will observe that companies as part of their marketing budget will keep additional 1B USD in cash for these type of situations.

As whistleblower act has been promoted in US we have more to watch!





Wednesday, December 19, 2012

Teva will it follow the BMS way?


After the investor's day update last week that Teva will be saving around USD 2 Billion of cash going forward. Mr Jermy levin has started implementing the process. Today Teva announced that its scrapping a $300 million warehouse project in Philadelphia has been halted.

Levin recently laid out a 5-year plan to diversify the company's products and to save up to $2 billion in large part by making its manufacturing operations more efficient. 

In light of the evaluation, a spokesperson said in an emailed statement, "As such, we have made the decision to cease development plans for the proposed distribution center on Red Lion Road in Philadelphia. At this time we cannot elaborate further about plans for this property."

What will be interesting going forward that there will be more possibility that Teva will also collaborate with some big Asian generic/biopharma companies for small molecule development the same lines BMS did with research outsourcing to India based Biocon some years back..... As he was key stakeholder involved in the famous BMS- Biocon alliance in India. Will Jermy move that way only time will say? 



Monday, December 17, 2012

CRO's New Marketing game!

Today at one side I have been down with fever but one promotion by Quintiles intrigued me " Quintiles: your RA partner"


RA landscape has been the most interesting landscape both in terms of small molecules and bio generics....Abbott had already been a market leader in terms of Humira but Pfizer has big plans for capturing the market share and we need to look at how it’s going to go for its pricing so that it has quick approval from the regulatory bodies in European region...
Now we need to just see if quintiles is going to be trials partner for the major companies who are investing in this segment for both the big daddy’s and bio generics and generic manufacturers in the RA landscape as compared to oncology its comparative easy market entry......What will be the next strategy for Icon, Paraxel, PPD and convance?



Saturday, December 15, 2012

Teva the giant......Will it be major contributor in Pharma Consolidation?

Jermy Levin became a Teva CEO long time back and I think has completed his probation period. Teva as a company is very conservation on its approach in advancement in any particular space in terms of indication attractiveness and product opportunities. After long time I was hearing Jermy Levin speak about its move....Teva for some time has been dwindling in a particular frame of mind as being a generic player or move differently the innovative path. What I am very positive about is that Jermy Levin was one of kind who made difference for BMS and i hope that he will have better success story to be told in future for Teva.........Teva like Novartis will be a one of the key player of the next Pharma consolidation happening by year 2020

Friday, November 30, 2012

Sanofi with New MENA Strategy!


Some one year back I wrote about companies like Merck and Novartis opening their shop floors in Turkey and how Turkey going forward is becoming a hot destination  for drug marketing and promotion, in a recent progress Sanofi is looking for acquisition of Czech company Zentiva which is worth $2.6 Billion , the deal will help Sanofi accelerate its presence in the MENA region as Zentiva has strong presence in the region….last month there were update for Biosimilar development by companies for MENA region…..after India and China ……MENA is the next favorable destination going forward
MENA: Middle East and North Africa